How far are induced pluripotent stem cells from the clinic?

Ageing Research Reviews

Volumn 9, Issue 3, 2010, Pages 257-264

  Li, Meirong ^a   Chen, Meixia ^a   Han, Weidong ^a   Fu, Xiaobing ^a  

^a Institute for Basic Research   (China)

Author keywords

Directed reprogramming; Embryonic stem cells; Induced pluripotent stem cells; iPSC technology; Regenerative medicine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR SOX2; TRICHOSTATIN A; VALPROIC ACID;

CANCER CELL; CANCER SUSCEPTIBILITY; CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INSERTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; INDUCED PLURIPOTENT STEM CELL BASED THERAPY; MICROENVIRONMENT; MOLECULAR STABILITY; MYELOID PROGENITOR CELL; NEURAL STEM CELL; NEUROEPITHELIUM; NONHUMAN; ONCOGENE C MYC; PANCREAS ISLET BETA CELL; PLURIPOTENT STEM CELL; PURIFICATION; REGENERATIVE MEDICINE; RESEARCH ETHICS; REVIEW; STEM CELL TRANSPLANTATION; TERATOMA; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 77952670047     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2010.03.001     Document Type: Review

References (86)

1. Aalto-Setala K., Conklin B.R., and Lo B. Obtaining consent for future research with induced pluripotent cells: opportunities and challenges. PLoS Biol. 7 (2009) e42
2. Aasen T., Raya A., Barrero M.J., Garreta E., Consiglio A., Gonzalez F., Vassena R., Bilić J., Pekarik V., Tiscornia G., Edel M., Boue S., Izpisua, and Belmonte J.C. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26 (2008) 1276-1284
3. Agapova L.S., Ivanov A.V., Sablina A.A., Kopnin P.B., Sokova O.I., Chumakov P.M., and Kopnin B.P. P53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints. Oncogene 18 (1999) 3135-3142
4. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., Chiba T., and Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321 (2008) 699-702
5. Atlasi Y., Mowla S.J., Ziaee S.A., and Bahrami A.R. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int. J. Cancer 120 (2007) 1598-1602
6. Balasubramanian S., Babai N., Chaudhuri A., Qiu F., Bhattacharya S., Dave B., Parameswaran S., Carson S., Thoreson W.B., Sharp J.G., Rao M., and Ahmad I. Non cell-autonomous reprogramming of adult ocular progenitors: generation of pluripotent stem cells without exogenous transcription factors. Stem Cells 27 (2009) 3053-3062
7. Belmonte J.C., Ellis J., Hochedlinger K., and Yamanaka S. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat. Rev. Genet. 10 (2009) 878-883
8. Blelloch R., Venere M., Yen J., and Ramalho-Santos M. Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell 1 (2007) 245-247
9. Buchholz D.E., Hikita S.T., Rowland T.J., Friedrich A.M., Hinman C.R., Johnson L.V., and Clegg D.O. Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells 27 (2009) 2427-2434
10. Chen Y., Shi L., Zhang L., Li R., Liang J., Yu W., Sun L., Yang X., Wang Y., Zhang Y., and Shang Y. The molecular mechanism governing the oncogenic potential of sox2 in breast cancer. J. Biol. Chem. 283 (2008) 17969-17978
11. Chen Z., Xu W.R., Qian H., Zhu W., Bu X.F., Wang S., Yan Y.M., Mao F., Gu H.B., Cao H.L., and Xu X.J. Oct4, a novel marker for human gastric cancer. J. Surg. Oncol. 99 (2009) 414-419
12. Daniela F., Vescovi A.L., and Bottai D. The stem cells as a potential treatment for neurodegeneration. Methods Mol. Biol. 399 (2007) 199-213
13. Di S.B., Prigione A., and Broccoli V. Efficient genetic reprogramming of unmodified somatic neural progenitors uncovers the essential requirement of Oct4 and Klf4. Stem Cells Dev. 18 (2009) 707-716
14. Dixon J.A., Gorman R.C., Stroud R.E., Bouges S., Hirotsugu H., Gorman III J.H., Martens T.P., Itescu S., Schuster M.D., Plappert T., St John-Sutton M.G., and Spinale F.G. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation 120 Suppl. 11 (2009) 220-229
15. Dzierzak E., and Enver T. Stem cell researchers find their niche. Development 135 (2008) 1569-1573
16. Eminli S., Utikal J., Arnold K., Jaenisch R., and Hochedlinger K. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells 26 (2008) 2467-2474
17. Ensenat-Waser R., Pellicer A., and Simon C. Reprogrammed induced pluripotent stem cells: how suitable could they be in reproductive medicine?. Fertil. Steril. 91 (2009) 971-974
18. Feng B., Jiang J., Kraus P., Ng J.H., Heng J.C., Chan Y.S., Yaw L.P., Zhang W., Loh Y.H., Han J., Vega V.B., Cacheux-Rataboul V., Lim B., Lufkin T., and Ng H.H. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat. Cell Biol. 11 (2009) 197-203
19. Foster K.W., Liu Z., Nail C.D., Lie X., Fitzgerald T.J., Bailey S.K., Frost A.R., Louro I.D., Townes T.M., Paterson A.J., Kudlow J.E., Lobo-Ruppert S.M., and Ruppert J.M. Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 24 (2005) 1491-1500
20. Gai H., Leung E.L., Costantino P.D., Aguila J.R., Nguyen D.M., Fink L.M., Ward D.C., and Ma Y. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biol. Int. 33 (2009) 1184-1193
21. Ghosh Z., Wilson K.D., Wu Y., Hu S., Quertermous T., and Wu J.C. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS One 5 (2010) e8975
22. Han W.D., Chen M.X., Li M.R., Wu Z.Q., Zhao Y.L., Wang Y., Wang L.L., Yu L., and Fu X.B. Acclimatized induction reveals the multipotency of adult human undifferentiated keratinocytes. Cloning Stem Cells (2010) (Epub ahead of print)
23. Han W.D., Zhao Y.L., and Fu X.B. Induced pluripotent stem cells: the dragon awakens. BioScience 60 (2010) 278-285
24. Hanna J., Markoulaki S., Schorderet P., Carey B.W., Beard C., Wernig M., Creyghton M.P., Steine E.J., Cassady J.P., Foreman R., Lengner C.J., Dausman J.A., and Jaenisch R. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133 (2008) 250-264
25. Hochedlinger K., and Plath K. Epigenetic reprogramming and induced pluripotency. Development 136 (2009) 509-523
26. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., Okita K., and Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460 (2009) 1132-1135
27. Hu B.Y., Weick J.P., Yu J., Ma L.X., Zhang X.Q., Thomson J.A., and Zhang S.C. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl. Acad. Sci. U.S.A. 107 (2010) 4335-4340
28. Ichida J.K., Blanchard J., Lam K., Son E.Y., Chung J.E., Egli D., Loh K.M., Carter A.C., Di, Giorgio F.P., Koszka K., Huangfu D., Akutsu H., Liu D.R., Rubin L.L., and Eggan K. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 5 (2009) 491-503
29. Karumbayaram S., Novitch B.G., Patterson M., Umbach J.A., Richter L., Lindgren A., Conway A.E., Clark A.T., Goldman S.A., Plath K., Wiedau-Pazos M., Kornblum H.I., and Lowry W.E. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 27 (2009) 806-811
30. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., Wahl G.M., and Belmonte J.C. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460 (2009) 1140-1144
31. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., Ko S., Yang E., Cha K.Y., Lanza R., and Kim K.S. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4 (2009) 472-476
32. Kim J., Chu J., Shen X., Wang J., and Orkin S.H. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132 (2008) 1049-1061
33. Kim J.B., Greber B., Araúzo-Bravo M.J., Meyer J., Park K.I., Zaehres H., and Schöler H.R. Direct reprogramming of human neural stem cells by OCT4. Nature 461 (2009) 649-653
34. Kim J.B., Zaehres H., Wu G., Gentile L., Ko K., Sebastiano V., Araúzo-Bravo M.J., Ruau D., Han D.W., Zenke M., and Scholer H.R. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 454 (2008) 646-650
35. LaPar D.J., Kron I.L., and Yang Z. Stem cell therapy for ischemic heart disease: where are we?. Curr. Opin. Organ Transplant. 14 (2009) 79-84
36. Liao J., Wu Z., Wang Y., Cheng L., Cui C., Gao Y., Chen T., Rao L., Chen S., Jia N., Dai H., Xin S., Kang J., Pei G., and Xiao L. Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. Cell Res. 18 (2008) 600-603
37. Liu S.V. iPS cells: a more critical review. Stem Cells Dev. 17 (2008) 391-397
38. Locke J.E., Shamblott M.J., and Cameron A.M. Stem cells and the liver: clinical applications in transplantation. Adv. Surg. 43 (2009) 35-51
39. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., Clark A.T., and Plath K. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2883-2888
40. Lyssiotis C.A., Foreman R.K., Staerk J., Garcia M., Mathur D., Markoulaki S., Hanna J., Lairson L.L., Charette B.D., Bouchez L.C., Bollong M., Kunick C., Brinker A., Cho C.Y., Schultz P.G., and Jaenisch R. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc. Nat. Acad. Sci. U.S.A. 106 (2009) 8912-8917
41. Maherali N., Ahfeldt T., Rigamonti A., Utikal J., Cowan C., and Hochedlinger K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3 (2008) 340-345
42. Maherali N., and Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3 (2008) 595-605
43. Marión R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., Fernandez-Capetillo O., Serrano M., and Blasco M.A. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460 (2009) 1149-1153
44. Mayhew C.N., and Wells J.M. Converting human pluripotent stem cells into beta-cells: recent advances and future challenges. Curr. Opin. Organ Transplant. 15 (2010) 54-60
45. Meissner A., Wernig M., and Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat. Biotechnol. 25 (2007) 1177-1181
46. Mikkelsen T.S., Hanna J., Zhang X., Ku M., Wernig M., Schorderet P., Bernstein B.E., Jaenisch R., Lander E.S., and Meissner A. Dissecting direct reprogramming through integrative genomic analysis. Nature 454 (2008) 49-55
47. Miyatsuka T., Kaneto H., Kajimoto Y., Hirota S., Arakawa Y., Fujitani Y., Umayahara Y., Watada H., Yamasaki Y., Magnuson M.A., Miyazaki J., and Hori M. Ectopically expressed PDX-1 in liver initiates endocrine and exocrine pancreas differentiation but causes dysmorphogenesis. Biochem. Biophys. Res. Commun. 310 (2003) 1017-1025
48. Murray J.C., Stingl G., Kleinman H.K., Martin G.R., and Katz S.I. Epidermal cells adhere preferentially to type IV (basement membrane) collagen. J. Cell Biol. 80 (1979) 197-202
49. Nakagawa M., Yoyanagi M., Tanabe K., Takahashi T., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., and Yamanata S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26 (2008) 101-106
50. Nishikawa S., Goldstein R.A., and Nierras C.R. The promise of human induced pluripotent stem cells for research and therapy. Nat. Rev. Mol. Cell Biol. 9 (2008) 725-729
51. Okabe M., Otsu M., Ahn D.H., Kobayashi T., Morita Y., Wakiyama Y., Onodera M., Eto K., Ema H., and Nakauchi H. Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. Blood 114 (2009) 1764-1767
52. Okita K., Ichisaka T., and Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 448 (2007) 313-317
53. Peehl D.M., and Ham R.G. Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium. In Vitro 16 (1980) 516-525
54. Rageul J., Mottier S., Jarry A., Shah Y., Theoleyre S., Masson D., Gonzalez F.J., Laboisse C.L., and Denis M.G. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int. J. Cancer 125 (2009) 2802-2809
55. Ramalho-Santos M. iPS cells: insights into basic biology. Cell 138 (2009) 616-618
56. Raya A., Rodriguez-Piza I., Guenechea G., Vassena R., Navarro S., Barrero M.J., Consiglio A., Castella M., Río P., Sleep E., Gonzalez F., Tiscornia G., Garreta E., Aasen T., Veiga A., Verma I.M., Surralles J., Bueren J., Izpisua, and Belmonte J.C. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460 (2009) 53-59
57. Rolletschek A., and Wobus A.M. Induced human pluripotent stem cells: promises and open questions. Biol. Chem. 390 (2009) 845-849
58. Ruau D., Ensenat-Waser R., Dinger T.C., Vallabhapurapu D.S., Rolletschek A., Hacker C., Hieronymus T., Wobus A.M., Müller A.M., and Zenke M. Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere. Stem Cells 26 (2008) 920-926
59. Sahu S., Tosh D., and Hardikar A.A. New sources of beta-cells for treating diabetes. J. Endocrinol. 202 (2009) 13-16
60. Sanada Y., Yoshida K., Ohara M., Oeda M., Konishi K., and Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32 (2006) 164-170
61. Schenke-Layland K., Rhodes K.E., Angelis E., Butylkova Y., Heydarkhan-Hagvall S., Gekas C., Zhang R., Goldhaber J.I., Mikkola H.K., Plath K., and MacLellan W.R. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells 26 (2008) 1537-1546
62. Schmitz M., Temme A., Senner V., Ebner R., Schwind S., Stevanovic S., Wehner R., Schackert G., Schackert H.K., Fussel M., Bachmann M., Rieber E.P., and Weigle B. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br. J. Cancer 96 (2007) 1293-1301
63. Shi Y., Desponts C., Do J.T., Hahm H.S., Schöler H.R., and Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 3 (2008) 568-574
64. Sholl L.M., Long K.B., and Hornick J.L. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl. Immunohistochem. Mol. Morphol. 18 (2009) 55-61
65. Silva J., Barrandon O., Nichols J., Kawaguchi J., Theunissen T.W., and Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 6 (2008) e253
66. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., Hargus G., Blak A., Cooper O., Mitalipova M., Isacson O., and Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009) 964-977
67. Sommer C.A., Sommer A.G., Longmire T.A., Christodoulou C., Thomas D.D., Gostissa M., Alt F.W., Murphy G.J., Kotton D.N., and Mostoslavsky G. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 28 (2010) 64-74
68. Song Z., Cai J., Liu Y., Zhao D., Yong J., Duo S., Song X., Guo Y., Zhao Y., Qin H., Yin X., Wu C., Che J., Lu S., Ding M., and Deng H. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res. 19 (2009) 1233-1242
69. Stadtfeld M., Brennand K., and Hochedlinger K. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Curr. Biol. 18 (2008) 890-894
70. Sullivan G.J., Hay D.C., Park I.H., Fletcher J., Hannoun Z., Payne C.M., Dalgetty D., Black J.R., Ross J.A., Samuel K., Wang G., Daley G.Q., Lee J.H., Church G.M., Forbes S.J., Iredale J.P., and Wilmut I. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 51 (2009) 329-335
71. Sun N., Panetta N.J., Gupta D.M., Wilson K.D., Lee A., Jia F., Hu S., Cherry A.M., Robbins R.C., Longaker M.T., and Wu J.C. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc. Nat. Acad. Sci. U.S.A. 106 (2009) 15720-15725
72. Takahashi K., Narita M., Yokura M., Ichisaka T., and Yamanaka S. Human induced pluripotent stem cells on autologous feeders. PLoS One 4 (2009) e8067
73. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007) 861-872
74. Takahashi K., and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006) 663-676
75. Tanaka Y., Era T., Nishikawa S., and Kawamata S. Forced expression of Nanog in hematopoietic stem cells results in a gammadelta T-cell disorder. Blood 110 (2007) 107-115
76. Tokuzawa Y., Kaiho E., Maruyama M., Takahashi K., Mitsui K., Maeda M., Niwa H., and Yamanaka S. Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol. Cell. Biol. 23 (2003) 2699-2708
77. Trosko J.E. From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann. N. Y. Acad. Sci. 1089 (2006) 36-58
78. Wang A.Y., Ehrhardt A., Xu H., and Kay M.A. Adenovirus transduction is required for the correction of diabetes using Pdx-1 or Neurogenin-3 in the liver. Mol. Ther. 15 (2007) 255-263
79. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., Bernstein B.E., and Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448 (2007) 318-324
80. Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif. 41 Suppl. 1 (2008) 51-56
81. Yan X., Qin H., Qu C., Tuan R.S., Shi S., and Huang G.T. iPS cells reprogrammed from mesenchymal-like stem/progenitor cells of dental tissue origin. Stem Cells Dev. (2009) (Epub ahead of print)
82. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., and Thompson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007) 1917-1920
83. Zhao R., and Daley G.Q. From fibroblasts to iPS cells: induced pluripotency by defined factors. J. Cell Biochem. 105 (2008) 949-955
84. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., Trauger S., Bien G., Yao S., Zhu Y., Siuzdak G., Scholer H.R., Duan L., and Ding S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4 (2009) 381-384
85. Zhou Q., Brown J., Kanarek A., Rajagopal J., and Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455 (2008) 627-632
86. Zwi L., Caspi O., Arbel G., Huber I., Gepstein A., Park I.H., and Gepstein L. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 120 (2009) 1513-1523